🇮🇳IN
Sign In
IN

INDOUS

NSE

Indo Us Biotech Limited

₹66.50

+0.04(+0.06%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

INDOUS financial summary

For Mar 2026, Indo Us Biotech Limited reported revenue of ₹110 crore, which grew 5.8% from the previous year. Net profit was ₹13 crore, which fell 18.8% year on year, on an operating margin of 15%. Earnings per share came in at ₹6.54. Over the 5 years from Mar 2021 to Mar 2026, revenue changed at a compound annual rate of 23.0% and net profit at 21.1%. The highest operating margin in that period was 18% in Mar 2025. Annual results are available for 16 financial years, from Mar 2011 to Mar 2026.

Revenue₹110 crore
Net profit₹13 crore
Operating margin15%
EPS₹6.54

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer